WO2022063869A3 - Compounds for the treatment of viral infections - Google Patents

Compounds for the treatment of viral infections Download PDF

Info

Publication number
WO2022063869A3
WO2022063869A3 PCT/EP2021/076142 EP2021076142W WO2022063869A3 WO 2022063869 A3 WO2022063869 A3 WO 2022063869A3 EP 2021076142 W EP2021076142 W EP 2021076142W WO 2022063869 A3 WO2022063869 A3 WO 2022063869A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
viral infections
compounds
infections
covid
Prior art date
Application number
PCT/EP2021/076142
Other languages
French (fr)
Other versions
WO2022063869A2 (en
Inventor
Ulrich Betz
Gordon Philipp Otto
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of WO2022063869A2 publication Critical patent/WO2022063869A2/en
Publication of WO2022063869A3 publication Critical patent/WO2022063869A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention encompasses cMET inhibitors for use in the treatment of viral infections, including coronavirus infections such as COVID-19, alone or in combination with one or more additional therapeutic agents.
PCT/EP2021/076142 2020-09-24 2021-09-23 Compounds for the treatment of viral infections WO2022063869A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20198119.8 2020-09-24
EP20198119 2020-09-24

Publications (2)

Publication Number Publication Date
WO2022063869A2 WO2022063869A2 (en) 2022-03-31
WO2022063869A3 true WO2022063869A3 (en) 2022-05-05

Family

ID=72659002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/076142 WO2022063869A2 (en) 2020-09-24 2021-09-23 Compounds for the treatment of viral infections

Country Status (1)

Country Link
WO (1) WO2022063869A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117794924A (en) * 2021-08-13 2024-03-29 苏州爱科百发生物医药技术有限公司 Compounds useful as inhibitors of ATR kinase
CN115583939A (en) * 2022-11-04 2023-01-10 苏州莱安医药化学技术有限公司 Synthesis method of Tepontinib intermediate

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006959A1 (en) * 2007-07-12 2009-01-15 Merck Patent Gmbh Pyridazinone derivates
WO2009143211A2 (en) * 2008-05-21 2009-11-26 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
WO2010071837A1 (en) * 2008-12-19 2010-06-24 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of atr kinase
WO2010078897A1 (en) * 2009-01-08 2010-07-15 Merck Patent Gmbh Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
US20110257181A1 (en) * 2008-12-23 2011-10-20 Merck Patent Gesellschaft Mit Beschrankter Haftung Pyridazinone derivatives
EP3533787A1 (en) * 2016-10-27 2019-09-04 Fujian Cosunter Pharmaceutical Co., Ltd. Pyridone compound as c-met inhibitor

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006959A1 (en) * 2007-07-12 2009-01-15 Merck Patent Gmbh Pyridazinone derivates
WO2009143211A2 (en) * 2008-05-21 2009-11-26 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
WO2010071837A1 (en) * 2008-12-19 2010-06-24 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of atr kinase
US20110257181A1 (en) * 2008-12-23 2011-10-20 Merck Patent Gesellschaft Mit Beschrankter Haftung Pyridazinone derivatives
WO2010078897A1 (en) * 2009-01-08 2010-07-15 Merck Patent Gmbh Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
EP3533787A1 (en) * 2016-10-27 2019-09-04 Fujian Cosunter Pharmaceutical Co., Ltd. Pyridone compound as c-met inhibitor

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
EIERHOFF THORSTEN ET AL: "The Epidermal Growth Factor Receptor (EGFR) Promotes Uptake of Influenza A Viruses (IAV) into Host Cells", PLOS PATHOGENS, vol. 6, no. 9, 1 January 2010 (2010-01-01), US, pages e1001099, XP055873255, ISSN: 1553-7366, Retrieved from the Internet <URL:https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1001099&type=printable> DOI: 10.1371/journal.ppat.1001099 *
GARCIA GUSTAVO ET AL: "Antiviral Drug Screen of Kinase inhibitors Identifies Cellular Signaling Pathways Critical for SARS-CoV-2 Replication", BIORXIV, 25 June 2020 (2020-06-25), pages 1 - 29, XP055874182, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.06.24.150326v1.full.pdf> [retrieved on 20211217], DOI: 10.1101/2020.06.24.150326 *
ITO YOKO ET AL: "Influenza induces IL-8 and GM-CSF secretion by human alveolar epithelial cells through HGF/c-Met and TGF-[alpha]/EGFR signaling", AMERICAN JOURNAL OF PHYSIOLOGY - LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, vol. 308, no. 11, 1 June 2015 (2015-06-01), US, pages 1178 - 1188, XP055873192, ISSN: 1040-0605, Retrieved from the Internet <URL:https://journals.physiology.org/doi/pdf/10.1152/ajplung.00290.2014> DOI: 10.1152/ajplung.00290.2014 *
KASHIWAKURA YUJI ET AL: "Hepatocyte Growth Factor Receptor Is a Coreceptor for Adeno-Associated Virus Type 2 Infection", JOURNAL OF VIROLOGY, vol. 79, no. 1, 1 January 2005 (2005-01-01), US, pages 609 - 614, XP055873493, ISSN: 0022-538X, Retrieved from the Internet <URL:https://journals.asm.org/doi/pdf/10.1128/JVI.79.1.609-614.2005> DOI: 10.1128/JVI.79.1.609-614.2005 *
KEIKO RAUSCH ET AL: "Screening Bioactives Reveals Nanchangmycin as a Broad Spectrum Antiviral Active against Zika Virus", CELL REPORTS, vol. 18, no. 3, 1 January 2017 (2017-01-01), US, pages 804 - 815, XP055383635, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2016.12.068 *
SOLNIER JULIA ET AL: "Flavonoids: A complementary approach to conventional therapy of COVID-19?", PHYTOCHEMISTRY REVIEWS, KLUWER, NL, vol. 20, no. 4, 18 September 2020 (2020-09-18), pages 773 - 795, XP037533619, ISSN: 1568-7767, [retrieved on 20200918], DOI: 10.1007/S11101-020-09720-6 *
SUGIYAMA MICHAEL G. ET AL: "Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease", SCIENTIFIC REPORTS, vol. 11, no. 1, 1 December 2021 (2021-12-01), XP055872992, Retrieved from the Internet <URL:https://www.nature.com/articles/s41598-021-02432-7.pdf> DOI: 10.1038/s41598-021-02432-7 *

Also Published As

Publication number Publication date
WO2022063869A2 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
CR20220070A (en) Parp1 inhibitors
WO2022047065A3 (en) Compounds and methods for treatment of viral infections
WO2018042343A3 (en) Compounds that inhibit 3c and 3cl proteases and methods of use thereof
WO2015070224A3 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2009105513A8 (en) Novel compounds and methods for therapy
EP4316599A3 (en) Antiviral therapy
WO2022063869A3 (en) Compounds for the treatment of viral infections
WO2019209962A8 (en) Compounds and uses thereof
IL181909A0 (en) Phosphoindoles as hiv inhibitors
CR20230100A (en) Phospholipid compounds and uses thereof
WO2007019098A3 (en) Hiv integrase inhibitors
MX2023004188A (en) Phospholipid compounds and uses thereof.
EP4342473A3 (en) Compounds useful in hiv therapy
MX2024000349A (en) Compounds and uses thereof.
MX2021011488A (en) Compounds and uses thereof.
WO2019209948A8 (en) Compounds and uses thereof
MX2020010697A (en) Kit, composition and combination therapy for fragile x syndrome.
MX2024006769A (en) Compounds and uses thereof.
EA202192047A1 (en) COMPOUNDS AND THEIR APPLICATIONS
MX2021015333A (en) Casein kinase 1 inhibitors for use in the treatment of diseases related to dux4 expression such as muscular dystrophy and cancer.
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof
WO2005080549A3 (en) Trioxacarcins and their use against infections
WO2021202990A3 (en) Methods for the treatment of betacoronavirus infections
MY166063A (en) Intravenous antiviral treatments
WO2007117272A3 (en) Methods for treatment of hemorrhagic shock and related disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21782952

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21782952

Country of ref document: EP

Kind code of ref document: A2